Prostate Cancer Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Scott Tagawa, MD, MS FACP, discusses the impact of ADT on the clinical course of COVID-19 in patients with prostate cancer.
View More
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
View More
Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.
View More
Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
View More
Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.
View More
Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.
View More
Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.
View More
Dr Sokolova discusses the GENTleMEN study and important differences between somatic and germline testing for patients with prostate cancer.
View More
Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.
View More
Stay in the know.
OncNet Newsletter